Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Amit Sanyal, MD: A Clinician’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Feb
16
Today In Oncology
ASH Guidelines on Management of Newly Diagnosed and Relapsed/Refractory ALL in AYA Patients
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
Oncolytic Virus Triggers Immune System Against Glioblastoma Cells
Adjuvant Durvalumab in Resected Early-Stage NSCLC
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo